Oncological Safety of Skipping Axillary Lymph Node Dissection in Patients with Clinical N0, Sentinel Node-Positive Breast Cancer Undergoing Total Mastectomy

Jung Whan Chun,Eunhye Kang,Hong-Kyu Kim,Han-Byoel Lee,Hyeong-Gon Moon,Jong Won Lee,Wonshik Han

DOI: https://doi.org/10.1245/s10434-024-15049-7

IF: 4.339

2024-02-17

Annals of Surgical Oncology

Abstract:Abstract Objective This study aimed to determine whether sentinel lymph node biopsy (SLNB) alone could afford oncological outcomes comparable with axillary lymph node dissection (ALND) in patients with early breast cancer without palpable lymphadenopathy who underwent total mastectomy (TM) and were SLN-positive. Methods This study analyzed clinical data of 6747 patients with breast cancer who underwent TM between 2014 and 2018 in two tertiary hospitals in Korea. Overall, 643 clinical stage T1-3 N0 patients who did not receive neoadjuvant therapy and had one to two metastatic SLNs at the time of surgery were included. Propensity score matching was performed between the SLNB alone and ALND groups, adjusting for clinical T stage and number of metastatic SLNs. In total, 237 patients were allocated to each group. Results Mean number of metastatic SLNs was 1.2 for the SLNB group and 1.6 for the ALND group. With a median follow-up of 65.0 months, 5 year disease-free survival was 90.8% for the SLNB group and 93.9% for the ALND group (hazard ratio [HR] 1.35, 95% confidence interval [CI] 0.70–2.58; p = 0.36). 5 year ipsilateral locoregional recurrence-free survival (LRRFS) was not significantly different between the two groups (95.1% and 98.3% for the SLNB and ALND groups, respectively) [HR 1.86, 95% CI 0.69–5.04; p = 0.21]. In the SLNB group, patients who received radiation therapy (RT) showed superior 5 year LRRFS than patients who did not receive RT (100% vs. 92.9%; p = 0.02). Conclusion Collectively, our findings suggest that SLNB could afford comparable outcomes to ALND in patients with early breast cancer and one to two metastatic SLNs who underwent TM. Importantly, RT could decrease locoregional recurrence in patients who underwent SLNB alone.

oncology,surgery

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is whether sentinel lymph node biopsy (SLNB) alone can provide an oncological outcome equivalent to axillary lymph node dissection (ALND) in early - breast - cancer patients who are clinically N0 and sentinel - node - positive and have undergone total mastectomy (TM). Specifically, the study focuses on the following aspects:

1. **Locoregional recurrence and distant metastasis**: Compare the differences in 5 - year locoregional recurrence - free survival rate (LRRFS) and 5 - year distant metastasis - free survival rate (DMFS) between the SLNB group and the ALND group.
2. **The role of adjuvant radiotherapy**: Evaluate the effect of adjuvant radiotherapy (RT) on locoregional recurrence control in patients in the SLNB group.

### Research background

- **Traditional surgical methods**: Although traditional axillary lymph node dissection (ALND) has a solid foundation in local control, it is accompanied by a relatively high risk of complications, such as lymphedema and wound infection.
- **Minimally invasive surgical strategies**: In recent years, with the deepening of the understanding of breast cancer treatment, people have begun to explore more minimally invasive axillary management strategies, such as performing only sentinel lymph node biopsy (SLNB) to reduce surgical trauma and complications.

### Research objectives

This study aims to determine whether SLNB can replace ALND under the following conditions:
- Early - breast - cancer patients
- Clinically N0 (no obvious axillary lymph node enlargement)
- Sentinel - node - positive (1 - 2 metastatic sentinel lymph nodes)
- Undergoing total mastectomy (TM)

In addition, the study also explored the role of adjuvant radiotherapy in this specific population, especially its effect on locoregional recurrence control.

### Main conclusions

- **Overall survival and recurrence situation**: In the matched cohort, there were no significant differences in 5 - year locoregional recurrence - free survival rate (LRRFS) and 5 - year distant metastasis - free survival rate (DMFS) between the SLNB group and the ALND group.
- **The effect of adjuvant radiotherapy**: In the SLNB group, patients who received adjuvant radiotherapy showed a better 5 - year locoregional recurrence - free survival rate (LRRFS), although these patients usually had more unfavorable clinical features (such as higher pathological T and N stages).

In conclusion, this study shows that in eligible early - breast - cancer patients, performing only sentinel lymph node biopsy (SLNB) may be feasible, and adjuvant radiotherapy helps to improve locoregional control.